Exhibit 99.2
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
As previously announced, on February 8, 2023, Globus Medical, Inc., (Globus or the Company) entered into an
Agreement and Plan of Merger (the Merger Agreement) with NuVasive, Inc. (NuVasive) and Zebra Merger Sub Inc., a wholly owned subsidiary of the Company (Merger Sub). On September 1, 2023, pursuant to the terms
of the Merger Agreement, Merger Sub merged with and into NuVasive (the Merger), with NuVasive surviving as a wholly owned subsidiary of the Company. At the consummation of the Merger, each issued and outstanding share of common stock of
NuVasive, $0.001 par value per share (NuVasive Common Stock), was converted into 0.75 fully paid and non-assessable shares of the Companys Class A Common Stock, and the right to receive
cash in lieu of fractional shares (the Merger Consideration).
The unaudited pro forma condensed combined statements of
operations for the nine months ended September 30, 2023, and the year ended December 31, 2022, give effect to the Merger as if it had occurred on January 1, 2022. The unaudited pro forma condensed combined statement of operations for
the nine months ended September 30, 2023, combines the unaudited condensed consolidated statement of operations of Globus for the nine months ended September 2023, and the unaudited condensed consolidated statement of operations for NuVasive,
for the period from January 1, 2023, through August 31, 2023, prior to the closing of the Merger on September 1, 2023. The unaudited pro forma condensed combined statement of operations for the fiscal year ended December 31,
2022, combines the audited consolidated statement of operations of Globus for the fiscal year ended December 31, 2022, and the audited consolidated statement of operations of NuVasive for the fiscal year ended December 31, 2022. A pro
forma balance sheet as of September 30, 2023, is not presented as the Merger is reflected in the Companys consolidated balance sheet as of September 30, 2023, appearing in the Companys Quarterly Report on Form 10-Q filed on November 7, 2023.
The unaudited pro forma condensed combined financial information
has been prepared pursuant to Article 11 of Regulation S-X.
The historical consolidated
financial statements of Globus and NuVasive have been adjusted in the accompanying unaudited pro forma condensed combined financial information to give effect to pro forma events that are transaction accounting adjustments which are necessary to
account for the business combination, in accordance with Generally Accepted Accounting Principles (GAAP). The unaudited pro forma adjustments are based upon available information and certain assumptions that Globus management believes
are reasonable.
The unaudited pro forma condensed combined financial information should be read in conjunction with the accompanying
notes to the unaudited pro forma condensed combined financial information, as well as: (i) the unaudited condensed consolidated financial statements of the Company as of September 30, 2023 and for the nine months ended September 30,
2023 and 2022, appearing in the Companys Quarterly Report on Form 10-Q filed on November 7, 2023, (ii) the audited consolidated financial statements of the Company as of and for the fiscal year
ended December 31, 2022, appearing in the Companys Annual Report on Form 10-K filed on February 21, 2023 and (iii) the audited consolidated financial statements of NuVasive as of and for
the fiscal year ended December 31, 2022, appearing in NuVasives Annual Report on Form 10-K filed on February 22, 2023.
The Merger was accounted for as a business combination using the acquisition method with Globus as the accounting acquirer in accordance with
Accounting Standards Codification (ASC) Topic 805, Business Combinations. Under this method of accounting, the aggregate Merger Consideration was allocated to NuVasives assets acquired and liabilities assumed based upon their
estimated fair values at the date of completion of the Merger. The process of valuing the net assets of NuVasive immediately prior to the Merger, as well as evaluating accounting policies for conformity, is preliminary. Any differences between the
estimated fair value of the consideration transferred and the estimated fair value of the assets acquired and liabilities assumed was recorded as goodwill. Accordingly, the aggregate Merger Consideration allocation and related adjustments reflected
in this unaudited pro forma condensed combined financial information are preliminary and subject to revision based on a final determination of fair value.
The unaudited pro forma condensed combined financial information has been prepared for illustrative purposes only and is not necessarily
indicative of what the combined companys financial position or results of operations actually would have been had the combination occurred as of the dates indicated. The unaudited pro forma condensed combined financial information also should
not be considered indicative of the future results of operations or financial position of Globus.